Bansal Multi Ventures

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what's currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus' manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.